Ciclesonide (EENT)

Brand names: Omnaris
Drug class: Antineoplastic Agents

Usage of Ciclesonide (EENT)

Allergic Rhinitis

Symptomatic treatment of seasonal or perennial allergic rhinitis.

Generally provides symptomatic relief of rhinorrhea, nasal congestion, sneezing, and nasal itching.

Relate drugs

How to use Ciclesonide (EENT)

General

  • For therapeutic effectiveness, use at regular intervals.

    • Administration

    Intranasal Administration

    Administer by nasal inhalation using a metered-dose spray pump.

    Shake spray pump gently immediately prior to priming or use.

    Prior to initial use, prime spray pump by actuating 8 times. Prime pump after a period of nonuse (i.e., ≥4 days) by actuating once or until a fine spray appears.

    Clear nasal passages prior to administration.

    Tilt the head slightly forward; insert spray tip into one nostril, keeping bottle upright. Point the tip away from the nasal septum.

    Pump the drug into one nostril while holding the other nostril closed and concurrently inspiring through the nose. Repeat procedure for the other nostril.

    Wipe applicator with a clean tissue after use.

    To unblock nasal applicator, remove dust cap and gently pull upward to free applicator. Wash dust cap and applicator in warm water, dry, replace applicator on bottle, and reprime the pump.

    Dosage

    After initial priming, nasal spray pump delivers 50 mcg of ciclesonide per metered spray. Each bottle containing 12.5 g of ciclesonide nasal spray delivers 120 metered sprays, after which the correct amount of drug in each spray cannot be assured.

    Symptomatic relief usually is evident within 24–48 hours after initiation of therapy; further symptomatic improvement may occur over 1–2 weeks in seasonal allergic rhinitis or 5 weeks in perennial allergic rhinitis.

    Once symptoms are controlled, gradually reduce dosage to the lowest effective level.

    Pediatric Patients

    Seasonal Allergic Rhinitis Intranasal Inhalation

    Children ≥6 years of age: 100 mcg (2 sprays) in each nostril once daily (total dosage: 200 mcg daily).

    Perennial Allergic Rhinitis Intranasal Inhalation

    Children ≥12 years of age: 100 mcg (2 sprays) in each nostril once daily (total dosage: 200 mcg daily).

    Adults

    Seasonal Allergic Rhinitis Intranasal Inhalation

    100 mcg (2 sprays) in each nostril once daily (total dosage: 200 mcg daily).

    Perennial Allergic Rhinitis Intranasal Inhalation

    100 mcg (2 sprays) in each nostril once daily (total dosage: 200 mcg daily).

    Prescribing Limits

    Exceeding the maximum recommended daily dosage may only increase the risk of adverse systemic effects.

    Pediatric Patients

    Seasonal Allergic Rhinitis

    Children ≥6 years of age: Maximum 200 mcg (2 sprays in each nostril) once daily.

    Perennial Allergic Rhinitis

    Children ≥12 years of age: Maximum 200 mcg (2 sprays in each nostril) once daily.

    Adults

    Maximum 200 mcg (2 sprays in each nostril) once daily.

    Special Populations

    Hepatic Impairment

    Dosage adjustment not required. (See Special Populations under Pharmacokinetics.)

    Renal Impairment

    No specific dosage recommendations at this time.

    Geriatric Patients

    Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.

    Warnings

    Contraindications

  • Known hypersensitivity to ciclesonide or any ingredient in the formulation.

    • Warnings/Precautions

    Warnings

    Withdrawal of Systemic Corticosteroid Therapy

    Carefully monitor patients being switched from prolonged systemic corticosteroids to intranasal corticosteroids since corticosteroid withdrawal symptoms (e.g., joint pain, muscular pain, lassitude, depression), acute adrenal insufficiency, and/or severe symptomatic exacerbation of asthma or other clinical conditions may occur.

    In patients with asthma or other clinical conditions requiring long-term systemic steroids, rapid decreases in systemic corticosteroid dosages may cause severe symptom exacerbations.

    Immunosuppression

    Although risk with intranasal use is unknown, consider the possibility that corticosteroid-induced immunosuppression could occur. Avoid exposure to varicella and measles in previously unexposed patients and those who have not been properly immunized.

    If exposure to varicella or measles occurs in susceptible patients, consider administering varicella zoster immune globulin (VZIG) or immune globulin (IG), respectively. Consider treatment with an antiviral agent if varicella develops.

    Sensitivity Reactions

    Immediate hypersensitivity reactions or contact dermatitis may occur rarely.

    Use with caution in patients hypersensitive to other corticosteroids; cross-sensitivity may occur.

    General Precautions

    Systemic Corticosteroid Effects

    Exceeding recommended dosages or use in patients who are particularly sensitive to corticosteroid effects may cause systemic corticosteroid effects (e.g., menstrual irregularities, acneiform lesions, cushingoid features).

    If systemic effects occur, slowly discontinue drug therapy, according to accepted procedures for discontinuing oral corticosteroids.

    Nasopharyngeal Effects

    Rarely, localized candidal infections of the nose and/or pharynx reported. Treat suspected infections appropriately; may require discontinuance of ciclesonide therapy.

    Periodically examine nasal passages for signs of mucosal changes during long-term therapy (several months or longer).

    Avoid use until healing occurs in patients with recent nasal septal ulcers, nasal surgery, or nasal trauma.

    Concomitant Infections

    Use cautiously, if at all, in patients with clinical or asymptomatic Mycobacterium tuberculosis infections of the respiratory tract, untreated local or systemic fungal or bacterial infections, ocular herpes simplex, or systemic viral or parasitic infections.

    Ophthalmic Effects

    Increased IOP, glaucoma, and cataracts reported rarely with other intranasal corticosteroids; such effects not reported with ciclesonide.

    Closely monitor patients with a change in vision or a history of glaucoma and/or cataracts.

    Specific Populations

    Pregnancy

    Category C.

    Lactation

    Distributed into milk in rats; not known whether distributed into human milk.

    Other corticosteroids known to be distributed into milk. Caution if used in nursing women.

    Pediatric Use

    Safety not established in children <2 years of age.

    Seasonal allergic rhinitis: Efficacy not established in children <6 years of age.

    Perennial allergic rhinitis: Efficacy not established in children <12 years of age.

    Intranasal corticosteroids may reduce growth velocity in pediatric patients. Routine monitoring of growth (e.g., via stadiometry) recommended. Titrate dosage to lowest possible effective level.

    Geriatric Use

    Insufficient experience in patients ≥65 years of age to determine whether such patients respond differently than younger adults; select dosage with caution. (See Geriatric Patients under Dosage and Administration.)

    Hepatic Impairment

    Increased systemic exposure following oral inhalation. (See Special Populations under Pharmacokinetics and see Hepatic Impairment under Dosage and Administration.)

    Common Adverse Effects

    Headache, epistaxis, ear pain, nasopharyngitis, nasal discomfort, pharyngolaryngeal pain.

    What other drugs will affect Ciclesonide (EENT)

    Inhibitory potential of ciclesonide on CYP isoenzymes not studied; des-ciclesonide (the active metabolite) does not appear to inhibit or induce CYP isoenzymes in vitro.

    Specific Drugs

    Drug

    Interaction

    Comments

    Erythromycin

    No pharmacokinetic interaction with orally inhaled ciclesonide

    Ketoconazole

    Increases des-ciclesonide levels with orally inhaled ciclesonide

    Manufacturer recommends caution if used concomitantly with intranasal ciclesonide

    Salicylic acid

    No effect on plasma protein binding of des-ciclesonide

    Warfarin

    No effect on plasma protein binding of des-ciclesonide

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords

    AI Assitant